Michael Anthony, MD
General Practice · Starkville, MSNPI 1679641450
Payments from drug & device makers
Across 430 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi-aventis U.S. LLC$731
- Boehringer Ingelheim$718
- Lilly USA, LLC$415
- Amgen$373
- Novo Nordisk$350
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,217100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 132 | $2,357 |
| Sanofi-aventis U.S. LLC | 44 | $731 |
| Boehringer Ingelheim | 43 | $718 |
| Lilly USA, LLC | 24 | $415 |
| Amgen | 24 | $373 |
| Novo Nordisk | 22 | $350 |
| Mylan Specialty L.p. | 19 | $298 |
| Johnson & Johnson | 21 | $272 |
| Pfizer | 15 | $253 |
| AbbVie(2 entities) | 14 | $243 |
| Merck | 11 | $189 |
| E.r. Squibb & Sons, L.L.C. | 10 | $165 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $117 |
| Biohaven Pharmaceuticals, Inc. | 7 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Abbott | 3 | $63 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Bayer | 3 | $47 |
| Organon | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $34 |
| Inari Medical, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $25 |
| Mayne Pharma Commercial LLC | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $21 |
| GSK | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
How this compares
$7,228 in reported general payments places this provider in the 95th percentile of 674 general practice providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $104,197 |
| XareltoRivaroxaban | 100 | $102,634 |
| OzempicSemaglutide | 97 | $98,823 |
| JardianceEmpagliflozin | 82 | $80,110 |
| FarxigaDapagliflozin Propanediol | 72 | $60,571 |
| JanuviaSitagliptin Phosphate | 48 | $42,233 |
| TradjentaLinagliptin | 74 | $31,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $20,430 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 57 | $16,562 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $16,411 |
| MounjaroTirzepatide | 13 | $13,548 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $9,906 |
| MyrbetriqMirabegron | 28 | $8,566 |
| LinzessLinaclotide | 11 | $8,138 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 42 | $7,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $718 | $117,194168 claims |
| PfizerEliquis, Premarin | $253 | $111,693128 claims |
| Johnson & JohnsonXarelto | $272 | $102,634100 claims |
| Novo NordiskOzempic | $350 | $98,82397 claims |
| AstraZenecaFarxiga, Symbicort | $2,357 | $67,26587 claims |
| MerckJanuvia | $189 | $42,23348 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $16 | $27,49848 claims |
| Lilly USA, LLCMounjaro | $415 | $13,54813 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $8,56628 claims |
| AbbVieLinzess | $243 | $8,13811 claims |
| NovartisEntresto | $13 | $5,41728 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $80 | $5,06611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 general practice providers in Mississippi.
Other general practice in Starkville
- Monica JonesStarkville$4K
- Delphine ShannonGulfport$341K
- Chris GriffinRipley$13K
- William McClendonPascagoula$10K
- Erin GreenBrandon$10K
- Jason OlaivarGulfport$10K
- Jessica PerkinsNew Albany$9K
- Andrew HarrisJackson$8K
- Katie WassonRidgeland$7K
- Dustin PambianchiLexington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.